For gene editing using CRISPR/Cas9 technology on BCR-ABL junctions, we amplified a DNA sequence of K562 CML cells using primers for the e12(b1) transcript on BCR and the a3 transcript on ABL [21]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.